Baillie Gifford & Co. Sells 149,963 Shares of Twist Bioscience Co. (NASDAQ:TWST)

Baillie Gifford & Co. trimmed its position in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 15.2% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 834,339 shares of the company's stock after selling 149,963 shares during the period. Baillie Gifford & Co. owned 1.42% of Twist Bioscience worth $37,695,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Signaturefd LLC grew its holdings in Twist Bioscience by 63.0% during the third quarter. Signaturefd LLC now owns 792 shares of the company's stock worth $36,000 after purchasing an additional 306 shares during the period. EdgeRock Capital LLC acquired a new stake in shares of Twist Bioscience in the second quarter valued at approximately $43,000. Blue Trust Inc. boosted its stake in shares of Twist Bioscience by 2,912.8% during the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company's stock worth $58,000 after acquiring an additional 1,136 shares during the period. DekaBank Deutsche Girozentrale acquired a new position in shares of Twist Bioscience during the 2nd quarter worth approximately $61,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in Twist Bioscience by 21.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company's stock valued at $98,000 after acquiring an additional 381 shares during the period.

Twist Bioscience Stock Down 6.1 %

Shares of TWST traded down $2.77 during mid-day trading on Wednesday, hitting $42.49. 962,117 shares of the company's stock were exchanged, compared to its average volume of 941,048. The stock's 50-day simple moving average is $43.86 and its 200-day simple moving average is $45.95. Twist Bioscience Co. has a 52 week low of $18.59 and a 52 week high of $60.90.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Evercore ISI lifted their price objective on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an "outperform" rating in a research report on Tuesday, October 1st. JPMorgan Chase & Co. lifted their target price on shares of Twist Bioscience from $28.00 to $35.00 and gave the stock an "underweight" rating in a report on Monday, August 5th. Leerink Partners increased their price target on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a "market perform" rating in a report on Thursday, October 17th. Robert W. Baird boosted their price objective on Twist Bioscience from $40.00 to $46.00 and gave the stock an "outperform" rating in a report on Monday, August 5th. Finally, Barclays decreased their target price on Twist Bioscience from $60.00 to $55.00 and set an "overweight" rating on the stock in a research report on Monday, August 5th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $51.22.

Insiders Place Their Bets

In related news, SVP Paula Green sold 3,310 shares of the company's stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $43.21, for a total transaction of $143,025.10. Following the completion of the sale, the senior vice president now owns 84,585 shares of the company's stock, valued at $3,654,917.85. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other Twist Bioscience news, SVP Paula Green sold 3,310 shares of the business's stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $43.21, for a total transaction of $143,025.10. Following the completion of the transaction, the senior vice president now directly owns 84,585 shares in the company, valued at $3,654,917.85. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Dennis Cho sold 1,507 shares of the company's stock in a transaction on Monday, November 11th. The stock was sold at an average price of $48.00, for a total value of $72,336.00. Following the sale, the insider now owns 91,163 shares of the company's stock, valued at $4,375,824. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 94,518 shares of company stock worth $4,221,015 in the last 90 days. Company insiders own 3.92% of the company's stock.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.